Polymorphism in neprilysin gene affect the risk of Alzheimer's diasease in Finnish patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 12, 2004, Pages 1746-1748

  Helisalmi, S ^a,b   Hiltunen, M ^a,b   Vepsalainen S ^a,b   Iivonen, S ^a,b   Mannermaa, A ^a   Lehtovirta, M ^a,c   Koivisito, A M ^a,b   Alafuzoff, I ^a   Soininen, H ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c JORVI HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; MEMBRANE METALLOENDOPEPTIDASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FINLAND; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEP GENE; NEUROPATHOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETICS; RISK FACTOR;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; FEMALE; FINLAND; GENOTYPE; HUMANS; MALE; NEPRILYSIN; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 10044243940     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.036574     Document Type: Article

References (12)

1. Iwaia N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Aβ by neprilysin. Science 2001;292:1550-2.
2. Haouas H, Morello D, Lavenu A, et al. Characterization of the 5′ region of the CD10/neutral endopeptidase 24.11 gene. Biochem Biophys Res Commun 1995;207:933-42.
3. Yasojima K, Akiyama H, McGeer EG, et al. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci Lett 2001;297:97-100.
4. Lilius L, Forsell C, Axelman K, et al. No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients. Neurosci Lett 2003;337:111-13.
5. Oda M, Morino H, Maruyama H, et al. Dinucleotide repeat polymorphisms in the Neprilysin gene are not associated with sporadic Alzheimer's disease. Neurosci Lett 2002;320:105-7.
6. Sodeyama N, Mizusawa H, Yamada M, et al. Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes. J Neurol Neurosurg Psychiatry 2001;71:817-24.
7. Clarimón J, Muñoz FJ, Boada M, et al. Possible increased risk for Alzheimer's disease associated with neprilysin gene. J Neural Trans 2003;110:651-7.
8. Lehtovirta M, Soininen H, Hefisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 1996;46:413-19.
9. Hiltunen M, Mannermaa A, Thompson D, et al. Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. Neurology 2001;57:1663-8.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
11. Raymond ML, Rousset F. An exact test for population differentiation. Evolution 1995;49:1280-3.
12. Haiman CA, Stram DO, Pike MC, et al. A comprehensive haplolype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003;12:2679-92.